GLP-1 drugs are delivering measurable productivity gains before AI has even started

The disruption that’s already measurable

NZ Herald business editor Liam Dann asked on 12 September 2026 which force reshapes the economy first: AI or weight-loss drugs. For New Zealand business owners the honest answer is uncomfortable. AI’s economic case rests on productivity gains that have not fully materialised at scale, even as tech valuations have already priced them in. GLP-1’s case rests on behaviour change that is already happening, already measurable, and already showing up in the data.

Goldman Sachs analysts estimate GLP-1 drugs will deliver a 1% lift to US GDP through productivity and cost savings. That is not a forecast of something that might arrive. It is an estimate of value already in motion. In the US, as many as 18% of adults are now using GLP-1 drugs, with more than 20% of households affected, and that is before pill-form rollout and patent expiry flood the market with cheap generics.

New Zealand is not a spectator

Wegovy became available in New Zealand from June 2025, and about 18,000 Kiwis were prescribed it within the first months. By early 2026, an estimated 50,000 New Zealanders were using GLP-1 drugs. Crucially, neither Wegovy nor Mounjaro is publicly funded. Users pay out of pocket, which means this cohort is disproportionately higher-income, urban, and exactly the discretionary spenders retailers and hospitality operators care about most.

The consumer shift is not subtle. People on these drugs consume roughly 20% fewer calories and spend about 30% less on groceries. A Cornell University study from January 2026 found households cut grocery spending by about 5% within six months, with the sharpest cuts in processed and high-fat foods. Woolworths is already reporting a surge in protein-rich items like Greek yoghurt and cottage cheese.

Winners and losers on the export shelf

For a food-exporting economy this cuts both ways. NZTE’s exporter analysis, cited in the NZ Herald’s 9 September report, puts sweet and salty snacks, confectionery, baked goods and sugary drinks under structural pressure, while fresh produce, whole foods, high-protein dairy, lean meat, fish and seafood pick up tailwinds.

The risk is real for New Zealand’s biggest categories. In January 2026, ASB chief economist Nick Tuffley framed it well: “We’re not selling directly to shoppers any more, we’re supplying the ingredients that end up in their food.” That buffer is genuine but not unlimited. Softening US appetite for calorie-dense butter and cheese would hit two of our largest export earners directly.

The labour angle nobody is modelling

Here is the part most employers have missed. Harvard economist Rebecca Diamond, in a National Bureau of Economic Research working paper, found unemployed women increased their odds of getting a job by 26.9 percentage points after roughly 18 months on GLP-1, compared with a control group. The effect was attributed to a “first impression margin” at interview rather than on-the-job productivity.

With unemployment at 5.3% in the March 2026 quarter and Treasury forecasting 5.5% for 2026 before easing to 4.3% by 2030, any drug-driven lift in labour-force participation would be a real positive. It is not in Treasury’s model. Neither is the food-spend shift: Treasury’s May 2026 Budget update projects private consumption growth of 1.0% in 2026 rising to 3.0% thereafter, with no GLP-1 assumptions baked in.

The funding bomb ticking under the health budget

The fiscal warning comes from Britain. Mounjaro became the single most expensive medicine in NHS history within a year of wider rollout, reaching NZ$1.3 billion in 2025/26, and that was with only 1% of eligible patients funded. New Zealand has hundreds of thousands who would meet the clinical criteria. Pharmac has placed Wegovy on its Options for Investment list but made no funding decision, and none of that liability sits in any official budget scenario.

What to do before the next quarter’s numbers land

The baseline is set: Stats NZ recorded $214 billion in total business sales for the June 2026 quarter, with retail trade and accommodation at $32.6 billion. Those are the figures against which GLP-1-driven shifts will show up. Grocers should treat protein and functional foods as growth, and snacks and sugary drinks as structural decline, not a cyclical dip. Exporters should lean into high-protein dairy and lean protein. Employers should watch the participation evidence, and insurers need both a funded and unfunded Pharmac scenario in their models now. AI may yet deliver its promised boom. The point is that biology got there first, and it is not waiting for the software to catch up.

Sources

• Weight-loss drugs v AI: Which one will reshape the economy first – Liam Dann (2026-09-12)
• Weight-loss wonder drugs are about to transform the New Zealand economy. Here’s how (2026-09-09)
• How businesses are pivoting to meet the GLP-1 customer (2026-08-29)
• Weight loss drugs could boost chances of getting a job (2026-08-05)
• NZ must think smarter about funding billion-dollar drugs – ex-Pharmac chief (2026-08-07)
• Wegovy and Mounjaro for weight loss not funded – Pharmac (2026-05-14)
• When America goes on a diet, NZ farmers may feel the pinch (2026-01-12)
• Budget Economic and Fiscal Update 2026 (2026-05-28)
• Labour market statistics: March 2026 quarter (2026-05-06)
• Business financial data: June 2026 quarter (2026-09-08)